Skip to content

Study · Randomized controlled trial · n = 599 · 2007

4 results

Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.

Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L, Meurer J, Wallwiener D, Possinger K

Journal of clinical oncology : official journal of the American Society of Clinical Oncology1 Jun 2007Cited by 63 (Europe PMC)

PMID17577027 (opens in a new tab)DOI10.1200/jco.2006.08.8534 (opens in a new tab)PepBankPUB-17577027
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with node-positive breast cancer, exploratory overall survival analysis favored leuprorelin over CMF.

    In plain wordsIn women with node-positive breast cancer, exploratory survival analysis favored leuprorelin over CMF.

    Peptide
    Leuprolide
    Outcome
    IncreaseOverall survival
    Study

    n = 599

    Comparator
    Cyclophosphamide, methotrexate, and fluorouracil
    Analysis
    Exploratory
    Outcome group
    Mortality · Cancer
    Studied dose
    Every-3-month depotAs given in this study (human).

    Measurements

    Hazard ratio
    1.5
    reported survival comparison
    95% CI
    1.13 to 1.99
    hazard ratio
    P
    0.005
    comparison

    Source sentences

    Summary
    Exploratory overall survival analysis favored LAD-3M (HR, 1.50; 95% CI, 1.13 to 1.99; P = .005).
    1 context sentence
    Summary · context
    This randomized phase III trial was performed to compare the 3-monthly depot LHRH agonist leuprorelin acetate (LAD-3M; n = 299) and chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF; n = 300) in pre- or perimenopausal patients with ER-positive, node-positive breast cancer.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In pre- or perimenopausal women with node-positive breast cancer, recurrence-free survival was similar with leuprorelin and CMF.

    In plain wordsIn women with node-positive breast cancer, recurrence-free survival was similar with leuprorelin and CMF.

    Peptide
    Leuprolide
    Outcome
    No significant changeRecurrence-free survival
    Study

    n = 599

    Comparator
    Cyclophosphamide, methotrexate, and fluorouracil
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Every-3-month depotAs given in this study (human).

    Measurements

    Hazard ratio
    1.19
    LAD-3M or CMF
    95% CI
    0.94 to 1.51
    hazard ratio
    P
    0.15
    comparison

    Source sentences

    Summary
    With a median follow-up of 5.8 years, recurrence-free survival was similar for patients treated with LAD-3M or CMF (hazard ratio [HR], 1.19; 95% CI, 0.94 to 1.51; P = .15).
    1 context sentence
    Summary · context
    This randomized phase III trial was performed to compare the 3-monthly depot LHRH agonist leuprorelin acetate (LAD-3M; n = 299) and chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF; n = 300) in pre- or perimenopausal patients with ER-positive, node-positive breast cancer.
  3. 03HumanRandomized controlled trialSafety outcome

    In women with breast cancer, hot flushes were initially more pronounced with leuprorelin than CMF.

    In plain wordsIn women with breast cancer, hot flushes were initially more pronounced with leuprorelin than CMF.

    Peptide
    Leuprolide
    Outcome
    IncreaseHot flushes
    Study

    n: not reported in source

    Comparator
    Cyclophosphamide, methotrexate, and fluorouracil
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Every-3-month depotAs given in this study (human).

    Source sentences

    Summary
    Chemotherapy-related adverse effects such as nausea, vomiting, and alopecia were more common with CMF, whereas symptoms of estrogen suppression such as hot flushes and sweating were initially more pronounced with LAD-3M.
    1 context sentence
    Summary · context
    This randomized phase III trial was performed to compare the 3-monthly depot LHRH agonist leuprorelin acetate (LAD-3M; n = 299) and chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF; n = 300) in pre- or perimenopausal patients with ER-positive, node-positive breast cancer.
  4. 04HumanRandomized controlled trialSafety outcome

    In women with breast cancer, sweating was initially more pronounced with leuprorelin than CMF.

    In plain wordsIn women with breast cancer, sweating was initially more pronounced with leuprorelin than CMF.

    Peptide
    Leuprolide
    Outcome
    IncreaseSweating
    Study

    n: not reported in source

    Comparator
    Cyclophosphamide, methotrexate, and fluorouracil
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Every-3-month depotAs given in this study (human).

    Source sentences

    Summary
    Chemotherapy-related adverse effects such as nausea, vomiting, and alopecia were more common with CMF, whereas symptoms of estrogen suppression such as hot flushes and sweating were initially more pronounced with LAD-3M.
    1 context sentence
    Summary · context
    This randomized phase III trial was performed to compare the 3-monthly depot LHRH agonist leuprorelin acetate (LAD-3M; n = 299) and chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF; n = 300) in pre- or perimenopausal patients with ER-positive, node-positive breast cancer.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.